The p53-Mdm2 Pathway: Targets for the Development of New Anticancer Therapeutics

Publisher： Bentham Science Publishers

E-ISSN： 1875-5607|3|3|257-270

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.3, Iss.3, 2003-05, pp. : 257-270

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents

By  

Current Cancer Drug Targets, Vol. 18, Iss. 8, 2018-10 ,pp. : 749-772

Bentham Science Publishers

Access to resources Recommend Favorite

MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting

By  

Current Cancer Drug Targets, Vol. 5, Iss. 1, 2005-02 ,pp. : 3-8

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Modeling Approaches in the Discovery of New Drugs for Anti-Cancer Therapy: The Investigation of p53-MDM2 Interaction and its Inhibition by Small Molecules

By  

Current Medicinal Chemistry, Vol. 17, Iss. 28, 2010-09 ,pp. : 3142-3154

Bentham Science Publishers

Access to resources Recommend Favorite

P53 Mdm2 Inhibitors

By  

Current Pharmaceutical Design, Vol. 18, Iss. 30, 2012-10 ,pp. : 4668-4678

Bentham Science Publishers

Access to resources Recommend Favorite

Small Molecule Inhibitors of the p53-MDM2

By  

Current Medicinal Chemistry, Vol. 15, Iss. 17, 2008-07 ,pp. : 1720-1730

Bentham Science Publishers

Access to resources Recommend Favorite